Apomorphine can increase cutaneous inhibition of motor activity in Parkinson's disease

Effects of Medications and Subthalamic Nucleus-Deep Brain Stimulation on the Cutaneous Silent Period in Patients With Parkinson's Disease

OBJECTIVES

We sought to evaluate whether the cutaneous silent period (CSP) could be an electrophysiological indicator reflective of the effects of therapy for Parkinson's disease (PD), including anti-PD medications or deep brain stimulation (DBS).

MATERIAL AND METHODS

We recorded the CSP in 43 patients with PD prior to and following the administration of medication during a pre-DBS evaluation (30 cases) and the "on" and "off" states of subthalamic nucleus DBS (13 cases). The CSP was elicited from the abductor pollicis brevis muscle by an electrical stimulation of the index finger that was 2, 4, and 15 times stronger than the sensory threshold (ST). We measured changes in latencies, including the onset, duration, and end of CSP, and waveform scores from 0 to 3. The correlation between the CSP score and unified PD rating score part III (UPDRS-III) also was assessed.

RESULTS

The onset latency and duration of CSP were significantly different between high (15ST) and low-strength stimulations (2ST and 4ST). However, there were no significant latency changes (onset, duration, end of CSP) before and after receiving medication, or during the on and off state of the DBS. Anti-PD medications substantially increased the CSP waveform score only in the 4ST state. However, the waveform score significantly increased in all stimuli states during the DBS-on state. Both medication and the DBS-on state decreased the UPDRS-III. Nevertheless, there was no statistically significant correlation between the UPDRS-III and CSP waveform scores.

CONCLUSION

Different onset latencies and the duration of CSP between low- and high-strength stimuli support the hypotheses proposing two different reflex pathways. Despite being independent from the UPDRS-III, the CSP may be an electrophysiological indicator reflective of the changes in inhibitory activity to the spinal α-motoneuron in response to anti-PD medications and DBS.

Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature

BACKGROUND

Transcranial magnetic stimulation (TMS) has been used in both physiological studies and, more recently, the therapy of Parkinson's disease (PD). Prior TMS studies in healthy subjects and other patient populations demonstrate a slight risk of seizures and other adverse events. Our goal was to estimate these risks and document other safety concerns specific to PD patients.

METHODS

We performed an English-Language literature search through PudMed to review all TMS studies involving PD patients. We documented any seizures or other adverse events associated with these studies. Crude risks were calculated per subject and per session of TMS.

RESULTS

We identified 84 single pulse (spTMS) and/or paired-pulse (ppTMS) TMS studies involving 1091 patients and 77 repetitive TMS (rTMS) studies involving 1137 patients. Risk of adverse events was low in all protocols. spTMS and ppTMS risk per patient for any adverse event was 0.0018 (95% CI: 0.0002-0.0066) per patient and no seizures were encountered. Risk of an adverse event from rTMS was 0.040 (95% CI: 0.029-0.053) per patient and no seizures were reported. Other adverse events included transient headaches, scalp pain, tinnitus, nausea, increase in pre-existing pain, and muscle jerks. Transient worsening of Parkinsonian symptoms was noted in one study involving rTMS of the supplementary motor area (SMA).

CONCLUSION

We conclude that current TMS and rTMS protocols do not pose significant risks to PD patients. We would recommend that TMS users in this population follow the most recent safety guidelines but do not warrant additional precautions.

Differential effect of baclofen on cortical and spinal inhibitory circuits

OBJECTIVE

The cutaneous silent period (SP) is a spinal inhibitory reflex, which suppresses activity in spinal motor nuclei. Transcranial magnetic stimulation (TMS) elicits a cortical SP, which represents GABA(B) receptor-mediated inhibition of cortical excitability. Baclofen as a strong GABA(B) agonist effectively reduces muscle hypertonia, however, it is not known whether intrathecal baclofen (ITB) may modulate spinal inhibitory circuits.

METHODS

We evaluated clinical and neurophysiological effects of ITB in ten patients with severe spasticity due to spinal cord injury (n = 9) and chronic progressive multiple sclerosis (n = 1). Neurophysiological assessment included H reflex and cutaneous and cortical SPs, before and 15, 30, 60, 90, 120, and 180 min after ITB bolus administration.

RESULTS

ITB suppressed soleus H reflex as early as 15 min after lumbar bolus injection; MAS scores declined after 1 h. Cortical SP end latency and duration increased progressively with a significant maximum 3h following ITB bolus, whereas cutaneous SP latency and duration did not change significantly.

CONCLUSION

The present findings suggest that baclofen does not affect the cutaneous SP, but prolongs the cortical SP.

SIGNIFICANCE

The spinal inhibitory circuitry of the cutaneous SP is not modulated by GABA(B) receptor-mediated activity, in contrast to the cortical inhibitory circuitry of the cortical SP, which is subject to powerful GABA(B) control.

Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation

Single or paired pulse paradigms of transcranial magnetic stimulation (TMS) provide several parameters to test motor cortex excitability, such as motor threshold (MT), motor evoked potential (MEP) amplitude, electromyographic silent period to cortical stimulation (CSP) and intracortical facilitation (ICF) or inhibition (ICI). Various changes in TMS parameters, revealing motor cortex dysfunction, were found in patients with Parkinson's disease (PD). For instance, low MT and increased MEP size disclosed an enhanced corticospinal motor output at rest, while reduced ICF and failure of MEP size increase during contraction suggested defective facilitatory cortical inputs, particularly for movement execution. Inhibitory cortical pathways were also found less excitable at rest (reduced ICI) and sometimes during contraction (shortened CSP). By restoring cortical inhibition, dopaminergic drugs and deep brain stimulation probably overcome the difficulty to focus neuronal activity onto the appropriate network required for a specific motor task. The application of repetitive TMS trains over motor cortical areas also showed some effect on cortical excitability, opening perspectives to consider the motor cortex as a target for therapeutic neuromodulation in PD. However, systematic studies of cortical excitability remained to be performed in large series of patients with PD, taking into account disease stage, clinical symptoms and medication influence.

Influence of transcutaneous electrical nerve stimulation on cutaneous silent periods in humans

The cutaneous silent period (CSP) is a spinal inhibitory reflex mediated by A-delta fibers. Ten healthy subjects underwent assessment of the effect of high-frequency transcutaneous electrical nerve stimulation (TENS) on the CSP. Surface electromyographic (EMG) recordings were obtained from thenar muscles following recurrent nociceptive digit II stimulation. Group average CSP duration was shortened relative to baseline recordings following 15 min of TENS. The amount of exteroceptive EMG inhibition was slightly increased due to a concomitant suppression of transcortical long-loop reflexes, which may be present within the CSP. Thus, TENS exerts an influence on both inhibitory and excitatory circuits involved in protective reflexes. These effects are likely mediated at the spinal segmental level through TENS-associated presynaptic inhibition of nociceptive A-delta fibers. The findings are in agreement with a known opiate-insensitive mechanism of TENS at the spinal level, and a previously reported insensitivity to fentanyl of CSPs.

Abnormal sensorimotor integration is related to disease severity in Parkinson's disease: a TMS study

Hyperexcitability of the motor system has been reported in Parkinson's disease (PD). We evaluate how cutaneous afferents modulate motor excitability in PD patients and whether abnormal modulation is correlated to parkinsonian symptoms. Digital stimulation causes abnormal enhancement of motor responses in patients. This effect may be one of the features of motor hyperexcitability in PD. Cutaneomotor hyperexcitability correlates with clinical scores, suggesting that abnormal processing of cutaneous inputs might contribute to the pathogenesis of parkinsonian symptoms.

Abnormal somatotopic arrangement of sensorimotor interactions in dystonic patients

The aim of the study was to detect abnormalities of sensorimotor interactions and their topographic distribution in the hand muscles of dystonic patients. We investigated the effect of electrical stimulation of the second (D2) and fifth (D5) fingers on the amplitude of motor evoked potentials (MEPs) in response to transcranial magnetic stimulation (TMS) and transcranial electrical stimulation (TES) in the relaxed first dorsal interosseous (FDI) and abductor digiti minimi (ADM) muscles on both sides of eight patients with unilateral hand dystonia (HD) and in four patients with cervical dystonia (CD). Six Parkinson's disease patients were used as the disease control group and 10 healthy subjects served as normal controls. For each muscle, the digital stimulation was applied to a contiguous finger (CF) and to a non-contiguous finger (NCF). The digital stimulation was set at three times the sensory threshold and preceded TMS or TES at intervals ranging from 10 to 100 ms. In normal subjects, a somatotopic inhibitory effect was detected, since the CF stimulation was significantly more powerful in determining the reduction of MEPs in response to TMS at intervals ranging from 20 to 50 ms. In dystonic patients, on the contrary, the somatopic effect was not present, because both CF and NCF stimulation evoked a consistent MEP inhibition and no significant difference was detected between the conditioning effect of CF and NCF stimulation. These abnormalities were present in the muscles of both the affected and unaffected hands of HD patients, as well as in CD patients. TES conditioning provoked MEP inhibition only at interstimulus intervals (ISIs) <40 ms. Significant MEP potentiation was found at ISIs of 20-40 ms to CF stimulation in Parkinson's disease patients, while there was no effect after NCF stimulation. These data suggest that MEP suppression in response to digital stimulation is preserved in dystonia, but the somatotopically distributed input-output organization of the sensorimotor interactions is lost in dystonic patients' hands. The comparison between TMS and TES experiments indicates that abnormalities may be present at both the spinal and the cortical level, at least in some patients. These findings suggest that a mechanism that normally operates in order to focus the effect of somatosensory afferences on the motor system may be impaired in dystonia. This abnormality seems specific to dystonia.

Applications of transcranial magnetic stimulation in movement disorders

The author reviews the applications of transcranial magnetic stimulation (TMS) in a series of movement disorders--namely, Parkinson's disease, corticobasal degeneration, multiple system atrophy, progressive supranuclear palsy, essential tremor, dystonia, Huntington's chorea, myoclonus, the ataxias, Tourette's syndrome, restless legs syndrome, Wilson's disease, Rett syndrome, and stiff-person syndrome. Single- and paired-pulse TMS studies have been done mainly for pathophysiologic purposes. Repetitive TMS has been used largely for therapy. Many TMS abnormalities are seen in the different diseases. They concur to show that motor cortical areas and their projections are the main target of the basal ganglia dysfunction typical of movement disorders. Interpretation has not always been clear, and sometimes there were discrepancies and contradictions. Largely, this may be the result of the extreme heterogeneity of the methods used and of the patients studied. It is premature to give repetitive TMS a role in treatment. Overall, however, TMS gives rise to a new, outstanding enthusiasm in the neurophysiology of movement disorders. There is reason to predict that TMS, with its continuous technical refinement, will prove even more helpful in the near future. Then, research achievements are reasonably expected to spill over into clinical practice.

L-Dopa decreases cutaneous nociceptive inhibition of motor activity in Parkinson's disease

OBJECTIVES

To estimate changes in motor inhibitory mechanisms at the spinal level in Parkinson's disease (PD) patients by measuring cutaneous silent responses to nociceptive stimuli in the course of L-Dopa therapy.

MATERIALS AND METHODS

Fourteen patients with idiopathic PD (Group 1) and 13 patients with other forms of parkinsonism (Group 2) participated in the study. The cutaneous silent period (CSP) from the hand and clinical scores (UPDRS, part III) were measured "off" therapy (T0), after a single dose of L-Dopa (T1) and 3 months after the beginning of L-Dopa daily therapy (T2).

RESULTS

At T0 the duration of the CSP was significantly prolonged in Group 1 and Group 2. At T1 and T2 the mean duration of the CSP significantly decreased in Group 1 (P < 0.05) and a significant correlation was found between the shortening of the CSP and the improvement of rigidity and bradikynesia in the upper limb.

CONCLUSIONS

Our findings show that L-Dopa decreases the cutaneous nociceptive inhibition of motor activity in PD patients. CSP may be useful to assess L-Dopa responsiveness during the clinical course of PD.

Overactivity of cervical premotor neurons in Parkinson's disease

OBJECTIVES

Cortical command to upper limb motor neurons is transmitted, in humans, not only through the monosynaptic corticomotor neuronal pathway, but also through cervical premotor neurons. Whether activity in this non-monosynaptic corticospinal pathway is modified in Parkinson's disease was explored.

METHODS

Ongoing EMG activity recorded in wrist extensors during tonic extension of the wrist is suppressed by a volley evoked by stimulating the superficial radial nerve. It has been shown that this cutaneous induced suppression is due to inhibition of transmission of the cortical command at a premotor neuronal level. By comparing the cutaneous induced EMG depression between 45 de novo parkinsonian patients and 23 age matched controls it has been possible to appreciate if and to what extent the "non-monosynaptic" part of the cortical command is modified in these patients.

RESULTS

At the early stage of the illness the EMG depression, reflecting the "non-monosynaptic" part of the cortical command, was bilaterally increased despite very asymmetric clinical status. When the duration of the disease was more than 36 months, EMG depression returned to its control level. No correlation was found between the amount of the EMG depression and parkinsonian symptoms before and after levodopa treatment.

CONCLUSION

Increase of the relative "non-monosynaptic" part of the cortical command could reflect a compensatory motor mechanism elaborated upstream from the motor cortex.